利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.02 秒)

    CYCLIC GUANIDINE IONIC LIQUID
    1.
    发明公开
    CYCLIC GUANIDINE IONIC LIQUID 审中-公开
    IONISCHEFLÜSSIGKEITAUS ZYKLISCHEM GUANIDIN

    公开(公告)号：EP2135862A1

    公开(公告)日：2009-12-23

    申请号：EP08720881.5

    申请日：2008-02-26

    申请人： Nippon Steel Chemical Co., Ltd.

    发明人： KAWADA, Atsushi ,  TASHIRO, Aya ,  KUMAGAI, Toshihiro

    IPC分类号： C07D233/48 ,  C07D417/04 ,  H01G9/038 ,  H01L31/04 ,  H01M10/36 ,  H01M14/00

    CPC分类号： H01M10/0568 ,  C07D233/44 ,  C07D233/48 ,  C07D239/12 ,  C07D239/14 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  H01G9/038 ,  H01G9/2013 ,  H01G9/2031 ,  H01G9/2059 ,  H01G11/58 ,  H01G11/62 ,  H01M14/005 ,  Y02E10/542 ,  Y02E60/13 ,  Y02P70/521

    摘要： Disclosed is an ionic liquid which is stable over a wide potential range and exhibits a high ionic conductivity. The ionic liquid comprises a cyclic guanidine salt represented by the following formula (1):

    wherein R 1 and R 2 each is independently an alkyl group or an alkoxyalkyl group, X is a methylene group, an oxygen atom, a sulfur atom, or R 3 N; R 3 is an alkyl group, an alkoxyalkyl group, or an acyl group; l, m, and n each is an integer in the range of 1-6; Y - is a monovalent anion such as (R 4 SO 2 ) 2 N - , R 4 SO 3 - , R 4 COO - , BF 4 - , PF 6 - , NO 3 - , (CN) 2 N - , (CHO) 2 N - , NCS - , R 4 OSO 3 - , R 4 SO 2 S - , and a halogen ion. The ionic liquid is useful for a variety of electrolytes, particularly for electrolytes of electrochemical cells.

    摘要翻译： 公开了一种离子液体，其在宽电势范围内是稳定的并且表现出高的离子导电性。 离子液体包含由下式（1）表示的环状胍盐：其中R 1和R 2各自独立地为烷基或烷氧基烷基，X为亚甲基，氧原子，硫原子或R 3 N; R 3是烷基，烷氧基烷基或酰基; l，m和n分别为1-6的整数; Y - 是一价阴离子，如（R 4 SO 2）2 N - ，R 4 SO 3 - ，R 4 COO - ，BF 4 - ，PF 6 - ，NO 3 - ，（CN）2 N - ，（CHO ）2 N - ，NCS - ，R 4 OSO 3 - ，R 4 SO 2 S - 和卤素离子。 离子液体可用于各种电解质，特别是用于电化学电池的电解质。

    N-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF
    2.
    发明公开
    N-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF 审中-公开
    N-二搭桥应用雄激素受体和方法的选择性调节剂

    公开(公告)号：EP1534663A1

    公开(公告)日：2005-06-01

    申请号：EP03731330.1

    申请日：2003-06-17

    申请人： University of Tennessee Research Foundation

    发明人： DALTON, James ,  MILLER, Duane, D. ,  MARHEFKA, Craig, A. ,  GAO, Wenqing

    IPC分类号： C07C233/05 ,  C07D211/72 ,  C07D239/02 ,  C07D233/44 ,  A61K31/65 ,  A61K31/44 ,  A61K31/505 ,  A61K31/415

    CPC分类号： C07D211/72 ,  A61K31/415 ,  A61K31/44 ,  A61K31/505 ,  A61K31/65 ,  C07C237/10 ,  C07C255/60 ,  C07D233/44 ,  C07D239/02

    摘要： This invention provides a class of androgen receptor targeting agents (ARTA) The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy, and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

    1-Carbocyclic aryl-2-mono or -bis(alkoxycarbonyl) guanidino ethanes, and methods for their preparation and the preparation therefrom of 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles
    4.
    发明公开
    1-Carbocyclic aryl-2-mono or -bis(alkoxycarbonyl) guanidino ethanes, and methods for their preparation and the preparation therefrom of 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles 失效
    1 - 碳环芳基-2-单或二（烷氧基羰基）-guani-dinoäthane，涉及它们的制备方法和这些4.5-二氢-2-烷氧基羰基-5-碳环芳基咪唑的制备。

    公开(公告)号：EP0001500A1

    公开(公告)日：1979-04-18

    申请号：EP78300450.0

    申请日：1978-10-04

    申请人： SYNTEX (U.S.A.) INC.

    发明人： Dvorak, Charles Alois ,  Beard, Colin Charles

    IPC分类号： C07D233/44 ,  C07C129/12 ,  A61K31/415

    CPC分类号： C07D233/44 ,  C07C279/24 ,  C07C309/69 ,  C07D317/58

    摘要： A method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and substituted aryl derivatives thereof is disclosed. The compounds are prepared by treating a 1-(carbocyclic aryl)-2-(2',3-bis-carbo- alkoxy)guanidino ethane of the formula
    where R is C, to C. linear or branched alkyl, R' is phenyl optionally substituted with the radical methylenedioxy or at least one hydroxy, halo, trifluoromethyl, C 1 to C 6 linear or branched alkoxy. C, to C 6 linear or branched alkyl; or 1-naphthyl or 2-naphthyl; and X is halo, mesyloxy or tosyloxy; with a protic solvent solution or dispersion of an alkali metal or alkaline earth metal hydroxide, carbonate or alkoxide. The reaction can alternatively be carried out on the corresponding (3'-mono-carboalkoxy)guanidino ethanes. These latter compounds can be prepared by treating the above bis(carboalkoxy)guanidino ethanes with an aprotic solvent solution or dispersion of an alkali metal or alkaline earth metal hydroxide, carbonate or alkoxide. These mono (carboalkoxy)guanidino ethanes are useful as psychotherapeutic agents in treating or palliating abnormal conditions, in mammals, which are relating to the central nervous system.

    摘要翻译： 一种用于制备4,5-二氢-2-烷氧基羰基-5-碳环芳咪唑方法和substituiertem芳基衍生物其游离缺失盘。 通过处理1-（碳环芳基）-2-（2分钟，3到烷氧羰基）的式胍基乙烷制备化合物... ...其中R是C1至C6的直链或支链烷基，R“是 上与自由基亚甲二氧基或至少一个羟基，卤素，三氟甲基，C1-C6直链或支链烷氧基，C1-C6直链或支链烷基取代的可选苯基; 或1-萘基或2-萘基; 和X是卤素，甲磺酰氧基或甲苯磺酰氧基; 质子与碱金属或碱土金属的氢氧化物，碳酸盐或醇盐的溶剂溶液或分散体。 该反应可以替代地在相应的（3分钟的单烷氧羰基）来进行胍基乙烷。 这些后面的化合物可通过在碱金属或碱土金属的氢氧化物，碳酸盐或醇盐的非质子性溶剂的溶液或分散体与治疗上述至（烷氧羰基）胍基乙烷来制备。 这些单（烷氧羰基）胍基乙烷可用作治疗或缓和在哺乳动物中异常的条件，这是与中枢神经系统精神治疗药物是有用的。